Skip to search formSkip to main contentSkip to account menu

pegnivacogin

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

RB 006

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study.
AIMS We sought to determine the feasibility of conducting percutaneous coronary intervention (PCI) in high-risk acute coronary… 
2014
2014
The effect of the REG2 Anticoagulation System on thrombin generation kinetics: a pharmacodynamic and pharmacokinetic first-in-human study
The REG2 Anticoagulation System consists of pegnivacogin, a subcutaneously administered aptamer factor IXa inhibitor, and its… 
2013
2013
Anticoagulation and Monitoring of a Novel and Reversible Factor IXa Inhibitor
Clinical Development Phases I‐III Regulatory, Quality, Manufacturing 
2012
2012
A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent
Summary.  Background:  The REG2 anticoagulation system consists of pegnivacogin, a subcutaneously administered aptamer factor IXa… 
2011
2011
Dose Selection for a Direct and Selective Factor IXa Inhibitor and its Complementary Reversal Agent: Translating Pharmacokinetic and Pharmacodynamic Properties of the REG1 System to Clinical Trial…
We performed detailed pharmacokinetic and pharmacodynamic modeling of REG1, an anticoagulation system composed of the direct… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)